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Background: Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been
reported but are not well characterized.
Objective: To evaluate the morphology and timing of cutaneous reactions after mRNA COVID-19 vaccines.
Methods: A provider-facing registry-based study collected cases of cutaneous manifestations after
COVID-19 vaccination.
Results: From December 2020 to February 2021, we recorded 414 cutaneous reactions to mRNA COVID-19
vaccines from Moderna (83%) and Pfizer (17%). Delayed large local reactions were most common,
followed by local injection site reactions, urticarial eruptions, and morbilliform eruptions. Forty-three
percent of patients with first-dose reactions experienced second-dose recurrence. Additional less common
reactions included pernio/chilblains, cosmetic filler reactions, zoster, herpes simplex flares, and pityriasis
rosea-like reactions.
Limitations: Registry analysis does not measure incidence. Morphologic misclassification is possible.
Conclusions: We report a spectrum of cutaneous reactions after mRNA COVID-19 vaccines. We observed
some dermatologic reactions to Moderna and Pfizer vaccines that mimicked SARS-CoV-2 infection itself,
such as pernio/chilblains. Most patients with first-dose reactions did not have a second-dose reaction and
serious adverse events did not develop in any of the patients in the registry after the first or second dose.
Our data support that cutaneous reactions to COVID-19 vaccination are generally minor and self-limited,
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and should not discourage vaccination. ( J Am Acad Dermatol https://doi.org/10.1016/j.jaad.2021.03.092.)
Key words: COVID-19; dermatology; Moderna; mRNA; Pfizer; public health; registry; SARS-CoV-2; vaccine;
vaccine reaction; delayed hypersensitivity; delayed inflammatory reaction; zoster; shingles; delayed large
local reaction; pityriasis rosea; local injection site reaction; erythromelalgia; urticaria; morbilliform; pernio;
chilblains; vesicular; erythema multiforme; filler; vasculitis.
INTRODUCTION








Clinical trials for both vac-
cines reported local injection
site reactions and systemic
symptoms after both
doses.1,2 Moderna addition-
ally noted delayed injection
site reactions (on/after day 8)
in 244 participants (0.8%)
after the first dose and in 68 participants (0.2%) after
the second dose.1 Moderna’s trial also described
vesicular, urticarial, exfoliative, macular, and papular
rashes, as well as facial swelling after cosmetic filler
injections.1 However, trials did not fully characterize
cutaneous reactions and did not describe whether
subjects with reactions after the first dose also had
reactions with the second.
Given the importance of widespread vaccination
in curbing the pandemic, we aimed to collect cases
of cutaneous side effects to the messenger RNA
(mRNA) COVID-19 vaccines (1) to describe the
morphology and timing of cutaneous reactions to
the Pfizer and Moderna vaccines and (2) to under-
stand differences in cutaneous reactions between the
2 vaccine doses to guide vaccine counseling.
METHODS
Our international registry of cutaneous manifes-
tations of SARS-CoV-2, established inMarch 2020 as a
collaboration between the American Academy of
Dermatology and the International League of
Dermatological Societies, expanded on December
24, 2020, to collect COVID-19 vaccine cutaneous
reactions, shortly after the Food and Drug
Administration issued Emergency Use
Authorizations (www.aad.org/covidregistry).3 Case
entry in the registry was open to health care workers
only. Collected data were deidentified.
The vaccine module of the registry collected dates
for both vaccine doses, morphology of cutaneous
reaction(s), timing and dura-
tion of reaction(s), and treat-
ments. Local site reactions
were defined as occurring
within 3 days of first-dose
vaccination and delayed
large local reactions were
defined as occurring 4 or
more days after the first
vaccination. A wheal at the
vaccine site was considered
an immediate or delayed
large local reaction, depend-
ing on timing.4 Conversely,
urticarial reactions were
defined as wheals in a distri-
bution beyond the injection
site.
We only included cutaneous reactions reported
after vaccination with Food and Drug
Administration-approved Pfizer or Moderna mRNA
vaccines, which at the time of analysis were being
administered mostly to health care workers and
elderly patients. Both vaccines require 2 doses
administered 3-4 weeks apart. All respondents who
only entered a cutaneous reaction to the first vaccine
dose were sent a follow-up email to solicit the
presence/absence of a cutaneous reaction to the
second vaccine dose. We contacted providers who
entered partially completed records and asked them
to complete all fields. We excluded records where
the provider was ultimately unable to provide key
variables (eg, vaccine brand or those in which
vaccine dose elicited a reaction). We used Stata
version 16 (StataCorp, LLC) to descriptively analyze
data. The Massachusetts General Brigham
Institutional Review Board exempted this study as
not human subject research.
RESULTS
From December 24, 2020, to February 14, 2021,
one or more cutaneous reactions to Moderna (83%)
or Pfizer (17%) COVID-19 vaccines were reported by
healthcare workers for 414 unique patients (Fig 1).
Median patient age was 44 years (interquartile range
[IQR], 36-59 years), and patients were 90% female,
78% White, and primarily from the United States
(98%; Table I). Cases were reported by
CAPSULE SUMMARY
d Across 414 cutaneous reactions to the
messenger RNA COVID-19 vaccines in
our registry, the most common
morphologies were delayed large local
reactions, local injection site reactions,
urticaria, and morbilliform eruptions.
d Less than 50% of patients with
cutaneous reactions after the first dose
experienced second-dose recurrence.
None reported serious adverse events.
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dermatologists (30%), other physicians (26%), mid-
level practitioners (8.8%), nurses (13%), and other
health care workers (22%).
Of the 414 patient records reviewed, information
about both vaccine doses was available for 180 (43%
of cases). Of these, 38/180 (21%) reported reactions
after the first dose only, 113/180 (63%) reported a
reaction after the second dose only, and 29/180
(16%) reported reactions to both doses
(Supplemental Fig 1 available via Mendeley at
https://data.mendeley.com/datasets/3t4zn67nc4).
Therefore, of the 67 patients who had a cutaneous
reaction to the first dose, 29 (43%) also had a
cutaneous reaction to the second dose. Of these 29
patients who reported reactions after both doses, 8
(28%) reported similar reactions to both doses, 8
(28%) reported a lesser reaction to the second dose,
and 13 (45%) reported a more robust reaction to the
second dose (Fig 2).
There were 343 unique reports of cutaneous
manifestations after the Moderna vaccination,
including 267 reported after the first dose and 102
reported after the second dose. The most common
cutaneous reactions were delayed large local re-
actions (n = 175 first; n = 31 second dose), local
injection site reaction (n = 117 first dose;
n = 69 second dose), urticaria (n = 16 first dose;
n = 7 second dose), morbilliform (n = 11 first dose;
7 second dose), and erythromelalgia (n = 5 first dose;
n = 6 second dose; Table II). Of the 343 patients with
cutaneous manifestations, only reactions to the first
dose were recorded for 215 (63%) patients, of whom
203 (94%) planned to receive the second dose and 12
(5.6%) did not plan to receive the second dose due to
concerns regarding their first-dose cutaneous re-
actions. Of those who reported information for
both doses (n = 130), 28 (22%) reported a reaction
to the first dose only, 76 (58%) reported a reaction to
the second dose only, and 26 (20%) reported re-
actions to both doses.
There were 71 reports of Pfizer vaccine cutaneous
manifestations, including 34 after the first dose and
40 after the second dose. The most common were
urticaria (n = 8, first dose; n = 6, second dose), local
injection site reaction (n = 8, first dose; n = 8, second
dose), and morbilliform rash (n = 6, first dose; n = 3,
second dose). Of the 71 cases with cutaneous
manifestations, only reactions to the first dose were
recorded for 21 (30%). These included patients who
were planning to receive their second dose (n = 12)
and patients not planning to receive their second
dose (n = 4) because of concerns regarding their first
cutaneous reactions. Of 50 patients with information
entered for both Pfizer doses, 10 (20%) reported
reactions after the first dose only, 37 (74%) after the
second dose only, and 3 (6.0%) after both doses.
Of the 414 records, 350 (85%) had timing infor-
mation. The median time from first vaccination to
onset of cutaneous symptoms was 7 days (IQR 2-8),
which occurred in 2 clusters, one between days 1
and 3 and the other between days 7 and 8 (Fig 3). The
majority of timing data came from patients with
reactions on the vaccinated arm only, with local
injection site reaction occurring a median of 1 day
(IQR 0-1) and delayed large local reactions occurring
median 7 days (IQR 7-8) after vaccination
(Supplemental Table I available via Mendeley at
https://data.mendeley.com/datasets/3t4zn67nc4).
The median time from second-dose vaccination to
cutaneous symptom onset was shorter, occurring at
day 1 (IQR 1-2). No urticaria or angioedema reports
after the first dose were immediate in onset; all came
after 1 day or more. Of 18 patients who reported
urticaria after their first vaccine dose for which
information about their second vaccine dose was
entered, urticaria developed only in 4 (22%) after
their second dose, with most (n = 3) reporting more
widespread urticaria.
Delayed large local arm reactions occurred pri-
marily afterModerna vaccination (94%) at amedian of
7 days (IQR 7-8) after the first vaccine and lasted a
median of 4 days (IQR 3-6; Fig 3). The reaction
occurred more quickly after the second vaccine dose,
at a median of 2 days (IQR 1-3) and lasted amedian of
3 days (IQR 2-5). For patients who had delayed large
local reactions after both doses (n = 11), 3 (27%) had a
larger reaction with the second dose. A smaller group
of patients who did not have any cutaneous reaction
after the first vaccine dose had a delayed large local
reaction to the second dose (n = 23), which occurred
a median of 2 days (IQR 1-3) after the second
vaccination. One hundred sixteen of the 207 (56%)
patients with delayed large local reactions also had
preceding local site injection reactions.
Less common reports of other cutaneous findings
with both vaccines included 9 reports of swelling at
the site of cosmetic fillers, 8 pernio/chilblains, 10
varicella zoster, 4 herpes simplex flares, 4 pityriasis
rosea-like reactions, and 4 rashes in infants of
vaccinated breastfeeding mothers.
DISCUSSION
In this registry-based study, we characterized the
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the novel Moderna and Pfizer mRNA COVID-19
vaccines. We observed a broad spectrum of reported
reactions after vaccination, from local injection site
reactions and delayed large local reactions, to urti-
caria and morbilliform eruptions, to more unusual
reactions, such as erythromelalgia, pernio/chilblains,
filler reactions, and pityriasis-rosea-like eruptions.
Of 67 patients with cutaneous findings after the first
dose and in whom information on both doses was
available, only 29 (43%) showed cutaneous symp-
toms after the second dose. This analysis should
provide reassurance to health care providers coun-
seling patients who had a cutaneous reaction after
the first dose of Moderna or Pfizer vaccine regarding
their second dose, as there were no cases of
anaphylaxis or other serious adverse events.5
The most commonly reported cutaneous
finding after vaccine administration was a delayed
large local reaction a median of 7 days after the
first vaccine dose, primarily after Moderna (94%).
Second-dose delayed reactions generally occurred
more quickly (day 2) and were generally lesser.
Similarly, the Moderna clinical trial described 0.8%
participants in whom delayed large local reactions
developed from the first dose after day 8, and
only 0.2% of participants experienced a reaction
with the second dose but did not link the
reactions from 1 dose to another and, thus, would
have missed detecting it if patients reacted more
quickly to the second dose.1,6 Rarely, delayed-
type hypersensitivity reactions have been
described after vaccination, with symptoms such
as large localized swelling, skin nodules, and/or
induration. These reactions, thought to be medi-
ated by T cells, have been attributed to ingredi-
ents such as neomycin or thimersol and have not
been considered as a contraindication to subse-
quent vaccination.4 Although the etiology of these
delayed large local reactions due to the Moderna
vaccine is unclear, a delayed-type hypersensitivity
reaction to the excipient polyethylene glycol is 1
potential etiology.6
In our registry, no severe sequelae were
identified after the second dose in patients expe-
riencing a delayed large reaction after the first
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• 92% Moderna
• 94% Female
• Median age 44
  (range 21-88)
• 100% vaccinated
  arm only
• 57% Moderna
• 89% Female
• Median age 39
  (range 26-69)
• Common sites
  were arms (68%), 
  trunk (57%), 
  and legs (46%)
• 65% Moderna
• 88% Female
• Median age 40
  (range 22-76)
• Common sites 
  were arms (62%),
  trunk (42%), and 
  legs (27%)
• 94% Moderna
• 93% Female
• Median age 47
  (range 22-88)
• 100% vaccinated
  arm only
• 77% Moderna
• 92% Female
• Median age 38
  (range 19-83)
• Common sites
  were arms (69%),
  face (31%), hands 
  (23%), and feet (15%)
*Shown in different skin tones
Fig 1. Timeline representing the time to onset and duration of the top 5 most common
dermatologic findings reported after the Moderna and Pfizer COVID-19 vaccines. The circles
represent median time to onset of the cutaneous reaction and lines represent median duration
of the cutaneous reaction. Supplemental Table I (available via Mendeley) provides detailed
information about the timing of vaccine reactions.
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Table I. Characteristics of cutaneous reactions reported after Moderna or Pfizer COVID-19 vaccination
Characteristic
Moderna vaccine
unique reports n (%)
(n = 343)
Pfizer vaccine






Dermatologist 96 (28) 30 (42) 126 (30)
Other physician 79 (23) 29 (41) 108 (26)
Physician assistant 10 (2.9) 1 (1.4) 11 (2.6)
Nurse practitioner 24 (6.9) 2 (2.8) 26 (6.2)
Nurse 49 (14) 5 (7.0) 54 (13)
Other medical professional 85 (25) 4 (5.6) 89 (21)
Patient age (median, IQR) 45 (36-60) 42 (36-54) 44 (36-59)
Patient sex (female) 314 (92) 60 (85) 374 (90)
Patient race/ethnicity
White 265 (77) 57 (80) 323 (78)
Asian 38 (11) 8 (11) 46 (11)
Black/African American 8 (2.3) 2 (2.8) 10 (2.4)
Hispanic/Latino 27 (7.9) 4 (5.6) 31 (7.5)
Unknown 4 (1.2) 0 4 (1.0)
Patient country
United States 337 (99) 66 (93) 403 (98)
Canada 2 (0.58) 1 (1.4) 3 (0.7)
Germany 1 (0.3) 1 (1.4) 2 (0.5)
Israel 0 1 (1.4) 1 (0.2)
Italy 0 1 (1.4) 1 (0.2)
United Kingdom 0 1 (1.4) 1 (0.2)
Puerto Rico 1 (0.3) 0 1 (0.2)
Guam 1 (0.3) 0 1 (0.2)
Prior SARS-CoV-2 infection
No 272 (79) 46 (65) 318 (77)
PCR1 7 (2.0) 4 (5.6) 11 (2.7)
Antibody1 2 (0.6) 2 (2.8) 4 (1.0)
Laboratory 1 but type unknown 1 (0.3) 0 1 (0.2)
Clinical suspicion only 10 (2.9) 2 (2.8) 12 (2.9)
Unknown 51 (15) 17 (24) 68 (16)
Past dermatologic history
None 296 (86) 53 (75) 349 (84)
Atopic dermatitis 12 (3.5) 5 (7.0) 17 (4.1)
Contact dermatitis 10 (2.9) 2 (2.8) 12 (2.9)
Psoriasis 6 (1.7) 3 (4.2) 9 (2.2)
Urticaria 5 (1.5) 2 (2.8) 7 (1.7)
Acne vulgaris 4 (1.2) 2 (2.8) 6 (1.4)
Other 10 (2.9) 4 (5.6) 14 (3.4)
Vaccine allergy history
None 316 (92) 64 (90) 380 (92)
Prior local site reaction 11 (3.2) 2 (2.8) 13 (3.1)
Prior urticaria 2 (0.6) 0 2 (0.5)
Other 3 (0.9) 1 (1.4) 4 (1.0)
Unknown 12 (3.5) 4 (5.6) 16 (3.9)
Past medical history
None 210 (61) 46 (65) 256 (62)
Hypertension 55 (16) 8 (11) 63 (15)
Obstructive lung disease 18 (5.2) 2 (2.8) 20 (4.8)
Morbid obesity 14 (4.1) 3 (4.2) 17 (4.1)
Diabetes mellitus 14 (4.1) 1 (1.4) 15 (3.6)
Cardiovascular disease 8 (2.3) 2 (2.8) 10 (2.4)
Rheumatologic disease 6 (1.7) 4 (5.6) 10 (2.4)
Malignancy 5 (1.5) 3 (4.2) 8 (1.9)
Other 29 (8.5) 11 (15) 40 (10)
Unknown 18 (5.2) 1 (1.4) 19 (4.6)
IQR, Interquartile range; PCR, polymerase chain reaction; 1, positive.
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corticosteroids, oral antihistamines, and/or pain-
relieving medications. These reactions resolved
after a median of 3-4 days. Antibiotics were not
required for resolution but were sometimes given
by providers concerned that the reaction might be
cellulitis, as reported elsewhere.7 Taken together,
these data provide reassurance to clinicians tasked




































21 95% 45% 1 (0-1) 1 (0-1)
Day 1* Day 2*
Delayed large





Urticaria 4 75% 75% 2 (1-3) 0 (0-2)
Day 2 Day 2
Fig 2. A depiction of the characteristics of the subset of patients who experienced the same
dermatologic finding after both the first and second COVID-19 vaccine doses. No patient
experienced anaphylaxis or another severe adverse event after the second COVID-19 vaccine
dose. *Different patient photos are used for local site injection reaction photos. All other photos
follow individual patients’ reaction after vaccine dose 1 and dose 2.
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Table II. Dermatologic findings reported after the Pfizer or Moderna COVID-19 vaccines. Patients who reported




(n = 267) n (%)
Moderna second dose
(n = 102) n (%)
Pfizer first dose
(n = 34) n (%)
Pfizer second dose
(n = 40) n (%)
Cutaneous reactions*,y
Delayed large local reaction 175 (66) 31 (30) 5 (15) 7 (18)
Local injection site reaction 143 (54) 71 (70) 8 (24) 10 (25)
Swelling 117 (44) 69 (68) 6 (18) 6 (15)
Erythema 132 (49) 68 (67) 6 (18) 8 (20)
Pain 94 (35) 60 (59) 8 (24) 7 (18)
Urticaria within 24 hours 0 2 (2.0) 0 1 (2.5)
Urticaria after 24 hours 13 (4.8) 5 (4.9) 9 (26) 7 (18)
Urticaria unknown timing 3 (1.1) 0 0 0
Morbilliform 11 (4.1) 7 (6.9) 6 (18) 3 (7.5)
Erythromelalgia 5 (1.9) 6 (5.9) 1 (2.9) 2 (5.0)
Flare of existing dermatologic conditionz 3 (1.1) 1 (1.0) 8 (24) 3 (7.5)
Vesicular 4 (1.5) 1 (1.0) 3 (8.8) 2 (5.0)
Pernio/chilblains 3 (1.1) 0 3 (8.8) 2 (5.0)
Zoster (VZV) 5 (1.9) 0 1 (2.9) 4 (10)
Angioedema 5 (1.9) 0 0 1 (2.5)
Pityriasis rosea 1 (0.4) 0 2 (5.9) 1 (2.5)
Erythema multiforme 3 (1.1) 0 0 0
Filler reaction 3 (1.1) 5 (4.9) 0 1 (2.5)
Vasculitis 2 (0.7) 0 1 (2.9) 0
Contact dermatitis 3 (1.1) 1 (1.0) 0 2 (5.0)
Reaction in breastfed infant 0 1 (1.0) 2 (5.9) 1 (2.5)
Onset of new dermatologic conditionx 2 (0.7) 0 0 2 (5.0)
Petechiae 1 (0.4) 2 (2.0) 1 (2.9) 0
Otherk 7 (2.6) 8 (7.8) 2 (5.9) 3 (7.5)
Systemic reactions in patients reporting
cutaneous reactions
Fatigue 58 (22) 63 (62) 11 (32) 13 (33)
Myalgia 55 (21) 63 (62) 10 (29) 10 (25)
Headache 46 (17) 54 (53) 9 (26) 6 (15)
Fever 18 (6.7) 42 (41) 4 (12) 4 (10)
Arthralgia 16 (6.0) 28 (27) 5 (15) 8 (20)
Nausea 15 (5.6) 28 (27) 4 (12) 3 (7.5)
Chills 14 (5.2) 47 (46) 4 (12) 5 (13)
Lymphadenopathy 13 (4.9) 9 (8.8) 2 (5.9) 3 (7.5)
Diarrhea 9 (3.4) 4 (3.9) 1 (2.9) 0
Other{ 10 (3.7) 10 (10) 4 (12) 1 (2.5)
PCR, Polymerase chain reaction.
*Providers were able to check off multiple dermatologic conditions in each patient.
yA subset of patients reporting vaccine reactions had prior laboratory-confirmed SARS-CoV-2 infection, including 11 who were PCR1 and 4
who were antibody1. Cutaneous reactions for these patients included local injection site reactions (n = 5), delayed large local reactions
(n = 3), urticaria (n = 2), morbilliform eruption (n = 1), pernio/chilblains (n = 1), erythromelalgia (n = 1), erythema multiforme (n = 1), pityriasis
rosea (n = 1), and reaction in breastfed infant (n = 1).
zIncludes flare of herpes simplex virus (n = 4), atopic dermatitis (n = 2), psoriasis (n = 2), urticarial vasculitis (n = 1), and unspecified eczema
(n = 2).
xIncludes Raynaud’s (n = 2), lichen planus (n = 1), and unspecified eczema (n = 1).
kOther cutaneous first-dose reactions included full-body skin pain/burning (n = 2), hypopigmentation (n = 2), Sweet’s-like fixed urticarial
plaque (n = 1), pseudovesiculated patches (n = 2), and spongiotic dermatitis (n = 1). Other cutaneous second-dose reactions included canker
sore on tongue (n = 1), aphthous ulceration on labium (n = 1), monomorphic papular eruption (n = 2), eczematous pigmented purpura
(n = 1), spongiotic dermatitis (n = 1), and full-body skin pain/burning (n = 2).
{Other systemic reactions included vomiting (n = 4, first dose; n = 3, second dose), nasal congestion (n = 4; n = 3), arm tingling/numbness
(n = 2; n = 1), syncope (n = 1; n = 2), dizziness (n = 1; n = 2), hot flashes (n = 1; first dose only), metallic taste in mouth (n = 1; first dose only),
and hematuria (n = 1; second dose only).
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delayed cutaneous arm reaction after their first
Moderna dose that (1) patients tolerated the
second dose without experiencing severe adverse
or allergic events, (2) the rash may recur the
second time but is, on average, likely to be less
severe and may develop faster, and (3) symptom-
atic therapies (eg, ice/pain-relief/antihistamines/
topical corticosteroids) can be used for treatment
without antibiotics.
We additionally observed reactions to Moderna
and Pfizer vaccines that had been noted after the
SARS-CoV-2 infection itself, including pernio/chil-
blains (eg, ‘‘COVID toes’’), erythromelalgia, and
pityriasis-rosea-like exanthems.3,8,9 That these exan-
themsmimic dermatologicmanifestations of COVID-
19 potentially suggests that (1) the host immune
response to the virus is being replicated by the
vaccine and (2) some components of these derma-
tologic manifestations of the virus are likely to be
from an immune response to the virus rather than
direct viral effects.10,11 Erythromelalgia and pityriasis
rosea have been noted in response to other vaccines,
such as those for influenza and hepatitis B, although
not commonly.12-14
We additionally identified rare patients with facial
swelling after both Moderna and Pfizer vaccines,
which were associated with prior use of injectable
cosmetic filler. This phenomenon was similarly
described in 3 subjects in Moderna trial reporting;
Pfizer did not report any such cases.1 These reactions
may represent a delayed hypersensitivity to filler
following the introduction of an immunologic
trigger,15 and have been previously noted after other
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Fig 3. Number of days from vaccination (day 0) until the development of a cutaneous reaction
after COVID-19 vaccine. A and B, First- and second-dose dermatologic findings, respectively,
after Moderna ( purple) or Pfizer (orange) vaccination. C and D, First- and second-dose
findings, respectively, restricted to patients who received Moderna and experienced the
development of a rash on the vaccinated arm, showing local injection site reactions (light blue)
and delayed large local symptoms (dark blue). A, Top left. B, Top right. C, Bottom left.D, Bottom
right.
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It is important to distinguish immediate hypersen-
sitivity reactions, defined by the Centers for Disease
Control and Prevention as including pruritus, urticaria,
flushing, and angioedema occurring within the first
4 hours of an injection, from similar reactions that
occur [4 hours after injection.18 This distinction is
particularly relevant for urticaria and angioedema,
which are potential contraindications for a second
vaccine dose.18 Although this registry captured time
between vaccination and skin reaction in days rather
than hours, none of the first-dose urticaria reports or
angioedema reports occurred on the day of vaccina-
tion and, therefore, would not be classified as imme-
diate hypersensitivity.Of the 18 urticaria reportswhere
informationwas available for both vaccine doses, only
4 had urticaria with their second dose and none
reported anaphylaxis, which should provide reassur-
ance regarding patients in whom urticaria develops
[4 hours after first vaccination. Importantly, allergic
cutaneous symptoms reported in this study, such as
urticaria, angioedema, and/or morbilliform eruptions,
may not be caused by allergy to the vaccine but instead
related to host immune response or an immunologic
reaction to nonsteroidal anti-inflammatory agents
commonly taken for pain and fever after vaccination.
Another limitation of this registry analysis in-
cludes an incomplete record follow-up. Because
providers only enter data at 1 point in time, patients
have differential lengths of follow-up. To overcome
this, we reached out via email to all providers after
such patients received second doses; nevertheless,
we still mostly report information regarding first
vaccine dose reactions. Reporting on the second
vaccine dose may be more common when there are
symptoms (rather than no reaction) to report. As
such, this reporting bias might result in our study
demonstrating a ‘‘worst case scenario’’ for the second
dose. Still, less than half of patients had recurrence
with the second dose. An additional limitation is that
the morphology description of vaccine reactions is
provider dependent. Future studies are needed to
classify morphologies with objectively classifiable
clinical images and histopathologic evaluation.
We are unable to measure the incidence of
cutaneous reactions to COVID-19 vaccination
through a registry-based study, which lacks a denom-
inator. There may be confirmation bias, as providers
were more likely to enter cases with severe or rare
manifestations. The registry noted 343 reactions from
the Moderna vaccine and only 71 from the Pfizer
vaccine, but it will require further population-level
data to understand whether this is a true difference or
related to reporting bias. As of February 22, 2021, 53%
of allocated vaccine doses in the United States were
Moderna and 47% were Pfizer.19,20
Ninety percent of the vaccine reactions were
reported in female patients. It is difficult to assess
whether there is a true sex-related difference in the
likelihood of the development of a cutaneous reac-
tion or whether it might reflect reporting bias or stem
from the health care workforce being 76% female.21
Further, vaccine reactions in this registry were pri-
marily in White (78%) patients, which highlights
important concerns about disparities in vaccine ac-
cess, health care access after experiencing a potential
side effect, differential likelihood of reporting to the
registry, and/or recognition of skin reactions by
health care providers in patients with skin of co-
lor.22,23 Patients were primarily located in the United
States (98%); at this time, there were no reports in the
registry of cutaneous reactions from patients in low-
and middle-income countries, raising attention to
global inequities in COVID-19 vaccine access.24
We characterize a spectrum of cutaneous reac-
tions reported with novel mRNA vaccines for
COVID-19. Certain dermatologic findings echo prior
vaccine hypersensitivity knowledge, while newer
findings, such as delayed large local reactions to the
Moderna vaccine and filler reactions may suggest
new immunologic mechanisms. Pernio/chilblains
post vaccine may suggest an immunologic connec-
tion to infection with SARS-CoV-2.8,9
CONCLUSIONS
Overall, our data support that cutaneous reactions
to COVID-19 vaccination are generally minor and
self-limited and should not discourage vaccina-
tion.1,2 Presence of a cutaneous reaction to the first
vaccine dose, when it appears[4 hours after injec-
tion, is not a contraindication to receiving the second
dose of the Pfizer or Moderna vaccine. No patients
with these findings experienced anaphylaxis or
another severe adverse event. Health care workers
must be aware of these potential vaccine reactions
and advise patients accordingly. Counseling patients
about potential benefits of receiving a COVID-19
vaccine is equally, if not more, important.
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